The following drugs were used: SP, SP methyl ester, β-ala
NKA, senkitide, NKA, NKB (Peninsula, Belmont, CA), CGRP 8-37, L-NAME,
staurosporine, tetrodotoxin, indomethacin, guanethidine,
phospharamidon, thiorphan, phorbol 12-myristate 13-acetate, pyrilamine,
genistein, carbachol, nickel hydrate, ω-conotoxin GVIA, EGTA (all
from Sigma Chemical, St. Louis, MO), captopril, NKA, verapamil,
nifedipine (Research Biochemicals International, Natick, MA), and
atropine sulfate (E. Merck, Darmstadt, Germany). The
NK3 and NK2 receptor
antagonists SR 142801,
(S)-(N)-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl)
propyl)-4-phenylpiperidin-4-yl)-N-methylacetamide, and SR 48968,
(S)-N-methyl-N[4-(4acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl]benzamide,
were kindly provided by Sanofi Recherché (Montpellier, France).
The stock solutions for all peptides used were prepared in
phosphate-buffered saline (PBS; 1–10 mM), kept in siliconized plastic
tubes, and maintained in a freezer at −18°C until use. Stock
solutions of indomethacin, staurosporine, and phorbol 12-myristate
13-acetate were made in absolute ethanol, but the final concentration
of ethanol did not exceed 0.05%, to avoid effects on either SP-induced
contraction or the tone of the preparations. All other drugs were
dissolved in PBS to the desired concentration just before use.